Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT07297160
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This early-phase trial tests a new type of immunotherapy called CAR T cells that are designed to recognize and attack cancer cells with a protein called CD70. The study includes 88 patients with lymphoma, myeloma, or certain solid tumors (like kidney cancer or sarcoma) that have returned or not responded to standard treatments. The main goal is to find a safe dose and understand side effects, while also checking if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
The Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD70-targeting CAR T cells (anti-CD70 chimeric antigen receptor T cells)
What this could lead to
If it works, this could point toward a new treatment option for patients with certain blood cancers and solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 88 participants, so it is too soon to know if the treatment is effective. There may be serious side effects, and the therapy is not yet FDA-approved.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.